Increased constitutional chromosome sensitivity to bleomycin in patients with hereditary non-polyposis colorectal cancer [HNPCC]

• Autorzy: Kladny J , Zajaczek S , Lubinski J
• Języki publikacji: EN

Abstrakty

EN

It has been suggested that mutagen sensitivity is a constitutional factor which may be useful in identification of patients with an increased risk for the development of tumors. In this study, the chromosome sensitivity to bleomycin was measured according to Hsu in patients with hereditary non-polyposis colorectal cancer (HNPCC), sporadic colorectal cancer and in control persons with no tumor history in family. In vitro lymphocytes were exposed to bleomycin according to Hsu and chromosomal damage was quantified by scoring breaks of 100 cells. A significant difference (P < 0.01) in the mean number of breaks per cell (b/c) was found between HNPCC patients (0.59 ± 0.14; n = 12; mean age 55.4 yrs) and control individuals (0.35 ± 0.13: n = 12; mean age 55.8 yrs). In contrast, patients with sporadic colorectal cancer showed a mean b/c value of 0.43 ± 0.14 (n = 14; mean age 63.4 yrs) which was not significantly higher than that in control individuals for this group (0.42 ± 0.15; n = 14; mean age 63.1 yrs). Selenium protected lymphocytes of HNPCC patients against bleomycin activity in vitro.

Słowa kluczowe

EN

chromosome sensitivity; lymphocyte; hereditary non-polyposis colorectal cancer; tumour; colorectal cancer; bleomycin; genotoxic effect

• Wydawca: -
• Czasopismo: Journal of Applied Genetics
• Rocznik: 1996
• Tom: 37
• Numer: 4
• Opis fizyczny: p.385-392

Twórcy

autor

Kladny J

• Department of Genetics and Pathology, Medical Academy, Powstancow Wlkp.72, 70-111 Szczecin, Poland

autor

Zajaczek S

• Department of Genetics and Pathology, Medical Academy, Powstancow Wlkp.72, 70-111 Szczecin, Poland

autor

Lubinski J

• Department of Genetics and Pathology, Medical Academy, Powstancow Wlkp.72, 70-111 Szczecin, Poland

Bibliografia

• AN J., HSIE W. (1993). Polymerase chain-reaction-based deletion screening of bleomycin-induced 6-thioguanine-resistant mutant in Chinese hamster ovary cells: The effects of an inhibitor and a mimic of superoxide dismutase. Mutat. Res. 289: 215-222.
• BENDER M.A., VIOLA M.V., FIORE J., THOMPSON M.H., LEONARD R.C. (1988). Normal G₂ chromosomal radiosensitivity and cell survival in the Cancer Family Syndrome. Cancer Res. 48: 2579-2584.
• BONDY M.L., SPITZ M.R., HALABI S., FUEGER J.J., SCHANTZ S.P., SAMPLE D., HSU T.C. (1993). Association between family history of cancer and mutagen sensitivity in upper aerodigestive tract cancer patients. Cancer Epidemiol Biomarkers Prev. 2: 103-106.
• CHERRY L.M., HSU T.C. (1983). Bleomycin-induced chromosome damage in lymphocytes of medullary thyroid carcinoma patients and their family members. Anticancer Res. 3: 367-372.
• FISHEL R., LESCOE M.K., RAO M.R.S., COPELAND N.G., JENKINS N.A., GARBER J., KANE M., KOLODNER R. (1993). The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027- 1038.
• FLORA DE S., DAGOSTINI F., IZZOTTI A., BALANSKY R. (1991). Prevention by N-acetyl-cysteine of benzo(a)pyrene clastogenicity and DNA adducts in rats. Mutat. Res. 250: 87-93.
• HSU T.C. (1987). Genetic predisposition to cancer with special reference to mutagen sensitivity. In Vitro Cell. Devel. Biol. 23: 591-603.
• HSU T.C., CHERRY L.M., SAMAAN N.A. (1985). Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet. Cytogenet. 17: 307-313.
• HSU T.C., JOHNSTON D. A., CHERRY L.M., RAMKISSOON D., SCHANTZ S.P., JESSUP J.M., WINN R.J., SHIRLEY L., FURLONG C. (1989). Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int. J. Cancer 43: 403-409.
• KŁADNY J., BIELICKI D., WIELONDEK M., MARLICZ K., LUBIŃSKI J. (1995). Clinical features of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) in Poland. Gut, suppl. 2: Vol. 37, A219.
• KUNE G.A., FIELD B., WATSON L.F., CLELAND H., MERENSTEIN D., VITETM L. (1993). Oral and pharyngeal cancer diet, smoking, alcohol and serum vitamin-a and beta carotene levels-a case- control study in men. Nutrition Cancer 20: 61-70.
• MOON R.C., McCORMICK D.L., METHA RG. (1983). Inhibition of carcinogenesis by retinoids. Cancer Res. 43: 2469-2475.
• NEVE J. (1993). Role essential et indications clinigues du selenium. Med. Hyg. 51: 741-746.
• NICOLAIDES N.C., PAPADOPOULOS N., LIU B., WEI Y-F., CARTER K.C., RUBEN S.M., ROSEN C.A., HASELTINE W.A., FLEISCHMANN R.D., FRASER C.M., ADAMS M.D., VENTER J.C., DUNLOP M.G., HAMILTON S.R., PETERSEN G.M., De la CHAPELLE A., VOGELSTEIN B., KINZLER K.W. (1994). Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371: 75-80.
• PANDIDA T.K., HITTELMAN W.N. (1995). Evidence of a chromatin basis for increased mutagen sensitivity associated with multiple primary malignancies of the head and neck. Int. J. Cancer 61: 738-743.
• PAPADOPOULOS N., NICOLAIDES N.C., WEI Y-F., RUBEN S.M., CARTER K.C., ROSEN C.A., HASELTINE W.A., FLEISCHMANN R.D., FRASER C.M., ADAMS M.D., VENTER J.C., HAMILTON S.R., PETERSEN G.M., WATSON P., LYNCH H.T., PELTOMÄKI P., MECKLIN J.P., de la CHAPELLE A., KINZLER K.W., VOGELSTEIN B. (1994). Mutation of a mutL homolog in hereditary colon cancer. Science 263: 1625-1629.
• PARSHAD R., SANFORD K.K., JONES G.M. (1983). Chromatid damage after G₂ phase X-irradiation of cells from cancer-prone individuals deficiency in DNA repair. Proc. Natl. Acad. Sci. USA, 80: 5612-5616.
• PERO R.W., MILLER D.G., LIPKIN M., MARKOWITZ M., GUPTA S., WINAWER S.J., ENKER W., GOOD R. (1983). Reduced capacity for DNA repair synthesis in patients with or genetically predisposed to colorectal cancer. JNCI 70: 867-875.
• RHYU M.S. (1996). Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. J. Natl. Cancer Inst. 88: 240-251.
• SCHANTZ S.P., SPITZ M.R., HSU T.C. (1990). Mutagen sensitivity in patient with head and neck cancers: a biologic marker for risk of multiple primary malignances. J.Natl. Cancer Inst. 82: 1773-1775.
• SCHRAUZER G.N. (1992). Selenium mechanistic aspects of anticarcinogenic action. Biol. Trace Elem. Res. 33: 51-62.
• SHAMBERGER R.J. (1970). Relationship of selenium to cancer. I. Inhibition effect of selenium on carcinogenesis. J. Nat. Cancer Inst. 44: 931-936.
• SHAMBERGER R.J., RUDOLPH G. (1966). Protection against carcinogenesis by antioxidants. Experientia 22: 216.
• STUBBE J., KOZARICH J.W. (1987). Mechanisms of bleomycin-induced DNA degradation. Chem. Rev. 87: 1107-1136.
• VASEN H.F.A., MECKLIN J.-P., MEERA KHAN P., LYNCH H.T. (1991). ThE International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG- HNPCC). Dis. Colon. Rectum 34: 424.
• WIENCKE J.K., SPITZ M.R. (1994). In vitro chromosomal assays of mutagen sensitivity and human cancer risk. Cancer Bull. 46: 238-246.
• ZAJĄCZEK S., SOLECKA-LENIEC L., BUCZKOWSKA M. (1987). Efekt antyklastogenny selenu wobec aberracji chromosomów i wymian chromatyd siostrzanych (SCE) indukowanych bleomycyną. Folia Med. Cracov. 28: 155-164.